hIL6-NOG

hIL6-NOG Mouse Model

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 13686-F
    sp/sp;ko/ko;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)#Jic/JicTac
  • 13686-M
    sp/sp;ko/y;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL6)#Jic/JicTac
  • Super immunodeficient NOG mouse expressing human IL-6 cytokine
  • Enhanced expansion of human monocytes following human HSC engraftment
  • May be useful for study of tumor-infiltrating macrophages
  • May be suitable host for hIL6-dependent acute myeloid leukemia (AML) samples
  • Applications in research involving cancer, immunology, regenerative medicine and human immune system engraftment

Origin:

The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The linearized hIL-6 transgene was injected into zygotes from NOD/Shi-IL2rg females x NOD/Shi-IL2rg males.  The transgenic hIL6- NOD/Shi-IL2rg mouse was crossed on to the NOG background to introduce the Prkdc scid mutation.  The mice were backcrossed onto the NOG background three times.  Taconic received stock in 2014, and the line was derived through embryo transfer.  


Availability:

Available now*
*Please note that advance order is encouraged for order of male mice. There is a minimal 4-week advance notice required on orders of male older than 3 weeks of age.

Color:

Albino

Species:

Mouse

Initial Publication:

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γ mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.

Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.

*The hIL6-NOG mouse has not been published yet. Initial publications above refer to the core NOG mouse.



Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the hIL6-NOG Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using this line, you must purchase under the for-profit terms and pricing.

For-profit users and users at foundations which are affiliated with for-profit entities: The hIL6-NOG Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610 EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758